Litcius/Paper detail

Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus

Haihai Jiang, Weiyu Peng, Jianxun Qi, Yan Chai, Hao Song, Yuhai Bi, Pramila Rijal, Haiyuan Wang, Babayemi Olawale Oladejo, Jinhua Liu, Yi Shi, George F. Gao, Alain Townsend, Yan Wu

2020mBio34 citationsDOIOpen Access PDF

Abstract

The immune system produces antibodies to protect the human body from harmful invaders. The monoclonal antibody (MAb) is one kind of effective antivirals. In this study, we isolated an antibody (Z2B3) from an H7N9 influenza virus-infected child. It shows cross-reactivity to both group 1 (N1) and group 2 (N9) neuraminidases (NAs) but is sensitive to N1 NA with a K432E substitution. Structural analysis of the NA-antibody fragment antigen-binding (Fab) complex provides a clue for antibody modification, and the modified antibody restored binding and inhibition to recently drifted N1 NA and regained protection against the variant influenza strain. This finding suggests that antibodies to NA may be a useful therapy and can be in principle edited to defeat drifted influenza virus.

Topics & Concepts

NeuraminidaseAntibodyMonoclonal antibodyVirologyVirusOriginal antigenic sinNeuraminidase inhibitorStrain (injury)Influenza A virusMedicineBiologyImmunologyAntigenic driftCoronavirus disease 2019 (COVID-19)Internal medicinePathologyDiseaseInfectious disease (medical specialty)Influenza Virus Research StudiesRespiratory viral infections researchRNA and protein synthesis mechanisms
Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus | Litcius